Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 12/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4797984 | 0.85 | HSD17B3 (0.38) | HSD17B3PDK1PDK2PDK3PDK4 | |
| SCHEMBL4797972 | 0.85 | HSD17B3 (0.38) | HSD17B3PDK1PDK2PDK3PDK4 | |
| SCHEMBL4802970 | 0.85 | HSD17B3 (0.48) | HSD17B3CACNA1B | |
| SCHEMBL4798294 | 0.84 | HSD17B3 (0.48) | HSD17B3CACNA1B | |
| SCHEMBL6389952 | 0.83 | HSD17B3 (0.58) | HSD17B3CACNA1B | |
| SCHEMBL4796700 | 0.83 | HSD17B3 (0.57) | HSD17B3NOTUM | |
| SCHEMBL4798138 | 0.82 | HSD17B3 (0.48) | HSD17B3NOTUM | |
| SCHEMBL6388533 | 0.80 | HSD17B3 (0.64) | HSD17B3CACNA1B | |
| Trifluoroacetic Acid SCHEMBL4796255 | 0.78 | HSD17B3 (0.54) | HSD17B3CACNA1B | |
| SCHEMBL4800907 | 0.77 | HSD17B3 (0.63) | HSD17B3NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417040-B2 | Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250753-A1 | Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogenase 3 | HSD17B3, HSD17B11, HSD17B1 | HSD17B3 1/4885NOTUM 465/4885CACNA1B 4310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.